DiaMedica Therapeutics Inc
NASDAQ:DMAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jiangxi Zhengbang Technology Co Ltd
SZSE:002157
|
CN |
|
P
|
Parque Arauco SA
SGO:PARAUCO
|
CL |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (14.3), the stock would be worth $-11.08 (276% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -8.1 | $6.3 |
0%
|
| Industry Average | 14.3 | $-11.08 |
-276%
|
| Country Average | 19.6 | $-15.23 |
-342%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
328.1m USD | -8.1 | -10.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365B USD | 20.1 | 87.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.6B USD | 14.2 | 24.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.5B USD | 15.6 | 20.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.8B USD | 22.2 | 28.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 14.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 41.8 | 37.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.2B AUD | 13.9 | 32.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
DiaMedica Therapeutics Inc
Glance View
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
